1

Greatbatch FY 2016 First Quarter

Earnings Call April 28, 2016

2

Forward-Looking Statement

Some of the statements made in the presentation whether written or oral may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of Securities Exchange Act of 1934, as amended, and involve a number of risks and uncertainties. These statements can be identified by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or “variations” or the negative of these terms or other comparable terminology. These statements are based on the company’s current expectations. The company’s actual results could differ materially from those stated or implied in such forward-looking statements. The company assumes no obligations to update forward-looking information, including information in this presentation, to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects.

3

Q1 Earnings Call Presenters

Thomas J. Hook President & CEO

Michael Dinkins Executive Vice President & Chief Financial Officer

4

Agenda

Michael Dinkins Financial Review Guidance update

Thomas J. Hook Summary Strategic Priorities

1. Drive Organic Growth 2. Integration of acquired companies to expand product

offering 3. Growth through innovation of complete medical systems

Question & Answer

5

Key Financial Metrics – Comparable Basis Three Months Ended

(Dollars in thousands, except per share data)

April 1, April 3, % 2016(1) 2015(2) Change

Sales $ 331,058 $ 357,867 (7 )% Organic Constant Currency Sales Growth (7 )%

GAAP Diluted EPS $ (0.30 ) $ 0.15 N/A Adjusted Diluted EPS(3) $ 0.42 $ 0.71 (41 )%

EBITDA $ 42,191 $ 57,377 (26 )% Adjusted EBITDA(3) $ 65,370 $ 72,045 (9 )% Adjusted EBITDA as a % Sales 19.7 % 20.1 %

(1) Comparable basis amounts for 2016 exclude the results of Nuvectra prior to its spin-off. (2) Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical. See the historical pro forma information presentation, which was filed with the SEC on Form 8-k on February 29, 2016, for a reconciliation to As Reported amounts. (3) Refer to Tables A and B at the end of this release for a reconciliation of adjusted amounts to GAAP. (4) The per share data has been rounded to $0.01 and therefore may not sum to the total.

Adjusted EPS(4) Notes

Q1 2015 Pro forma $ 0.71

Price (0.17) Price concessions to secure customer commitments for LTAs

Sales Volume (0.13) Growth in Neuromodulation customers offset by continued decline in Energy market, customer inventory reduction initiatives and product end of life (EOL)

Sales Mix/Productivity 0.08 Impact of productivity initiatives and initial phases on synergy plan

SG&A 0.12 Reduction driven by execution of synergy plan

RD&E (0.07) Customer Reimbursement timing and higher investments in selective projects

Interest & Other Gain Losses 0.01

Tax Impact (0.13) Increase in effective tax rate due to unfavorable mix of GAAP earnings and adjustments in Q1; Actual cash taxes are on target for approx. $10M for total year

Q1 2016 – Comparable Basis $ 0.42

6

Product Category Revenues Three Months Ended Comparable Basis

Product Line April 1, 2016(1) April 3,

2015(2) % Change

Advanced Surgical, Orthopedics, and Portable Medical $ 91,329 $ 105,773 (14 )%

Cardio and Vascular 133,650 138,084 (3 )%

Cardiac/Neuromodulation 95,895 98,866 (3 )%

Electrochem 11,672 17,710 (34 )%

Elimination of interproduct line sales (1,488 ) (2,566 ) (42 )%

Total Sales $ 331,058 $ 357,867 (7 )%

Organic Constant Currency Sales Increase (Decrease) (7)%

(1) Comparable basis amounts for 2016 exclude $1.2 million of Nuvectra revenue recognized prior to its spin-off. (2) Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical. See the historical pro forma information presentation, which was filed with the SEC on Form 8-k on February 29, 2016, for a reconciliation to As Reported amounts.

7

Advanced Surgical, Orthopedics, and Portable Medical

Negative impact due to safety stock build-up last year supporting manufacturing transfer

Timing of Orthopaedic customer product launches and inventory reduction initiatives

Price concessions to secure long term volume commitments

Reamer

Delivery System

Implant

(Sales in $ millions) Q1 R4Q Prior Qtr Sales $91 $404 $105 % total Company 27% 28% 29% Growth (Comparable Basis) -14% -7% -13%

Laparoscopic Devices

Arthroscopy Products

8

Cardio and Vascular

Price concessions to secure long term volume commitments

Customers working off EOL product inventory making for tough prior year comparable

Focus on high growth sectors

Complex, steerable catheter shafts for Electrophysiology market

Catheter shafts for peripheral and neuro vascular markets

Introducer

Steerable Sheath

Amounts in millions

Amounts in millions

(Sales in $ millions) Q1 R4Q Prior Qtr Sales $134 $558 $133 % total Company 40% 39% 37% Growth (Comparable Basis) -3% -3% 1%

Guidewires, Stylets & Accessories

Stents

Catheters & Sheaths

9

Cardiac/Neuromodulation

Battery

Feedthrough

Enclosure

Continued YoY growth in Neuromodulation

Customers tightened inventory, timing of product introductions and end of life (EOL) products

Price concessions to secure long term volume commitments

Coated Electrode

(Sales in $ millions) Q1 R4Q Prior Qtr Sales $96 $411 $111 % total Company 29% 29% 31% Growth (Comparable Basis) -3% 5% -12%

10

Electrochem

Amounts in millions

Continued weakness in the global Energy market

Battery Packs

Battery Cells

Battery Chargers

(Sales in $ thousands) Q1 R4Q Prior Qtr Sales $12 $53 $13 % total Company 4% 4% 4% Growth (Comparable Basis) -34% -34% -12%

11

Balance Sheet Metrics ($ in millions except for EPS)

Operating Cash Flow for the quarter was $30M. Increase in debt driven by $76M cash payment for Nuvectra Spin Off.

(in $ millions except ratios) Q1’16 2015*

Working Capital $318 $361

Working Capital Turnover** 4.5 4.0

Account Receivables $184 $207

Days Sales Outstanding 50 52

Net Inventory $267 $252

Days Inventory Outstanding 101 86

* 2015 Ratios calculated based on pro forma financials for combined company ** Q1 2016 Ratios estimated based on last 4 quarters for combined company *** Net Leverage Ratio and Interest Coverage ratios are calculated in line with debt covenants

(in $ millions except ratios) Q1’16 2015*

Total Debt $1,763 $1,714

Net Leverage Ratio (<6.5)*** 5.4 5.2

Interest Coverage Ratio (>3.0)*** 4.1 4.9

Adjusted RoE** 16.6% 15.0%

12

The company reconfirms its revenue, Adjusted EBITDA and Adjusted EPS guidance. The revenue guidance is $1.425 billion to $1.475 billion

The Adjusted EBITDA guidance is $320 million to $335 million.

For the full year 2016, we expect adjusted net income per diluted share to be in

the range of $3.00 to $3.35 on 31.5 million fully diluted shares outstanding.

For the second quarter of 2016 the Company expects revenue to be in the range of $355 million to $360 million.

Guidance

13

Selected Financial Guidance Items Affecting Cash Flow:

Maintenance Capital Expenditures to be in the range of $50 million - $60 million per year.

Depreciation & Amortization is expected to be $100 million - $105 million for 2016.

Stock compensation expense is expected to be approximately $14 million for 2016.

Working Capital is expected to be consistent with the prior year.

The 2016 adjusted effective tax rate is expected to be approximately 30%; cash taxes are expected to be approximately $10 million for the full year 2016

Other Operating expense is expected to be $55 million - $65 million for the full year 2016

Cash payment for Nuvectra Spin-off was $76 million. The two companies are independent and Greatbatch does not have any ownership in Nuvectra.

Guidance

14

Agenda Michael Dinkins

Financial Review Guidance update

Thomas J. Hook Summary Strategic Priorities

1. Integration of acquired companies

2. Drive Organic Growth 3. Growth through innovation

of complete medical systems

Question & Answer

15

Executive Summary

Q1 Financial Results in line with expectations

Difficult comparables to last year

CRM, Energy & FX headwinds continue to negatively affect results

Neuromodulation growth largely offsetting decline in CRM

2016 Guidance remains unchanged

16

Key Strategic Priorities

Drive Core product organic growth.

Integration of acquired companies.

Growth through complete medical device systems in partnership with customers.

17

Core Product Organic Growth Strengthen Customer Partnerships

Changed from functional to align with customer markets

INTEGER will use a single (sales) point of contact for our top strategic customers responsible for strategic relationship management

Global Accounts will coordinate all activities across INTEGER’s product categories

The Technical Solutions team will focus their growth strategy from discrete engineered components through co-developed devices

The Product Solutions team will focus on co-developed devices, INTEGER branded solutions and complete medical device systems in partnership with our customers

Smaller and single site customers shall be managed through the site customer service/operations resources

18

Integration Update

Tracking Extremely Well

Three organizational phases of integration completed

On track to achieve at least $25M of savings in 2016

Line of sight to achieve annual savings of $50M in 2017 and at least $60M in 2018

Years 2-3 largely driven by supply chain and manufacturing optimization

19

Growth through Complete Medical Device Systems VA

LUE

Engineered Medical

Components

Engineered Medical

Sub Assemblies

Differentiated Medical

Components &

Subassemblies

Transfer Devices

Co-Developed

Devices

Integer Designed Devices

Fully Branded Solutions

Medical Device

Systems

Product Solutions (More IP Focused)

SOLUTION COMPLEXITY

Technical Solutions (Traditional CMO)

The Integer strategy is to significantly increase our value to our customers by increasing the amount of business we have on the right side of the product continuum.

Global Accounts

20

Current Product Continuum Revenue Mix

Product Solutions,

20.4%

Technical Solutions,

79.6%

Legacy GB % of Sales

Product Solutions,

17.6%

Technical Solutions,

82.4%

Legacy LRM % of Sales

Product Solutions,

18.9%

Technical Solutions,

81.1%

Integer % of Sales

21

LRM provides… Greatbatch provides… INTEGER will provide…

Electrode Machining Electrode Coating Value added lead assembly

Cardiac Lead Components Cardiac Leads & MRI IP Vertically integrated lead solutions

Neuro connectors SCS Leads and Adaptors Vertically integrated lead solutions

IPG Components IPG Systems Comprehensive Long Term Partnerships

Technology Solutions

22

LRM provides… Greatbatch provides… INTEGER will provide…

Sensor Enabled Guidewires Catheter Shafts Peripheral Navigation Solutions

Microcatheter Solutions Hub and Valve molding Neurovascular and Drug Delivery Systems

Laparoscopic Tools Rechargeable Batteries &Wireless Energy Transfer

Portfolio of Tools with Wireless Rechargability

Arthroscopic Tools Wireless Power Portfolio of Wireless Surgical Products

Product Solutions

23

Questions & Answers

24

Appendix

25

2016 Annual and Q1 Effective Tax Rate Analysis 2016 Annual Effective Tax Rate (AETR):

Adjusted AETR is currently forecasted at ~30%

Our ETR is generated from the mix of income and tax rates in the various jurisdictions in which we do business:

US (35%) ; Mexico (~30%); Ireland (12.5%) ; Germany (~27.5%); France ( ~40%) ; Switzerland (~6%); Uruguay (~25%)

Net Operating Losses of ~$393M and $25M exist in the US and Switzerland, respectively.

Based on forecasted sources of income; we expect to utilize the NOL’s within 10 to 13 years. Cash tax savings are forecasted to be ~$137M No ETR benefit will result from NOL utilization as VA will be released through purchase accounting and will decrease Goodwill.

2016 Cash taxes (jurisdictions other than US and Switzerland) are estimated at ~$10M.

2016 Q1 ETR:

Adjusted Q1 ETR of ~ 42% on $22.5M of pre-tax income

Our adjusted effective tax rate for the first quarter of 2016 was approximately 42% as a result of the Company tax affecting its adjustments at the statutory rate, consistent with its adjusted diluted EPS methodology, but with earnings tax affected at the lower expected full-year effective tax rate for GAAP purposes as required. The impact from these differences is expected to reverse over the remaining three quarters and our full year adjusted effective tax rate is expected to be 30%.

The first quarter 2016 GAAP effective tax rate includes a $1.3 million discrete charge related to non-deductible spin-related expenses, which is added back for adjusted diluted EPS purposes.

ASC 740, Accounting for income taxes requires the impact of unusual or infrequently occurring items (e.g., non-deductible transaction costs associated with tax-free Spin) to be excluded from the calculation of the AETR and instead, to be recorded on a “discrete” basis in the quarter in which they occurred.

26

GAAP Reconciliation

a) As a result of our acquisition of Lake Region Medical in the fourth quarter of 2015 and in order to present our financial results in a form more comparable to other medical device companies and less acquisitive companies, during the third quarter of 2015 we began excluding intangible asset amortization for purposes of calculating adjusted net income and adjusted diluted EPS. Prior period adjusted amounts have been recalculated to exclude intangible amortization.

b) In 2013, we filed suit against AVX Corporation alleging they were infringing on our intellectual property. Given the complexity and significant costs incurred pursuing this litigation, during the second quarter of 2015, we began excluding these litigation expenses from adjusted amounts. This matter proceeded to trial during the first quarter of 2016 and a federal jury awarded Greatbatch $37.5 million in damages. Prior period adjusted amounts have been recalculated to exclude these costs.

c) Net of tax amounts computed using a 35% U.S., Mexico, Germany and France statutory tax rate, a 0% Swiss tax rate, a 25% Uruguay statutory tax rate, and a 12.5% Ireland statutory tax rate. Expenses that are not deductible for tax purposes (i.e. permanent tax differences) are added back at 100%.

d) During 2016 and 2015, we incurred costs primarily related to the transfer of our Beaverton, OR portable medical and Plymouth, MN vascular manufacturing operations to Tijuana, Mexico. Additionally, with the acquisition of Lake Region Medical, 2016 costs also include expenses incurred in connection with the closure of Lake Region Medical’s Arvada, Colorado site and the consolidation of its two Galway, Ireland sites initiated by Lake Region Medical in 2014.

e) During 2016, we incurred transaction and integration costs related to the acquisition of Lake Region Medical in October 2015. During 2015, we incurred costs related to the integration of CCC Medical Devices which was acquired in August 2014.

f) Costs primarily include legal and professional fees incurred in connection with the proposed spin-off of Nuvectra, which was completed in March 2016. g) Pre-tax amount is a gain of $1.3 million and $0.5 million for the 2016 and 2015 periods, respectively. h) The 2015 Federal R&D tax credit was enacted during the fourth quarter of 2015 and has been permanently reinstated. Amounts assume that the tax credit was effective at the beginning of the year for 2015. i) The per share data in this table has been rounded to the nearest $0.01 and therefore may not sum to the total. j) First quarter 2016 adjusted diluted weighted average shares includes 535,000 shares related to outstanding equity awards that were not dilutive for GAAP diluted EPS purposes.

Net Income and Diluted EPS Reconciliation Three Months Ended

April 1, 2016

April 3, 2015

(in thousands except per share amounts) Net

Income

Per Diluted Share

Net Income

Per Diluted Share

Net income (loss) as reported $ (12,660 ) $ (0.41 ) $ 8,008 $ 0.31 Adjustments:

Amortization of intangibles(a)(c) 6,691 0.21 2,366 0.09 IP related litigation (SG&A)(b)(c) 1,240 0.04 455 0.02 Consolidation and optimization expenses (OOE)(c)(d) 5,314 0.17 5,538 0.21 Acquisition and integration expenses (OOE)(c)(e) 6,511 0.21 46 — Asset dispositions, severance and other (OOE)(c)(f) 4,226 0.14 434 0.02 Gain on cost and equity method investments, net (other income, net)(c)(g) (846 ) (0.03 ) (324 ) (0.01 ) R&D Tax Credit(h) — — 400 0.02

Adjusted net income and diluted EPS(i) $ 10,476 $ 0.34 $ 16,923 $ 0.65 Adjusted diluted weighted average shares 31,253 26,219

27

Adjusted EBITDA reconciliation

GAAP Reconciliation

Three Months Ended April 1, April 3, (dollars in thousands) 2016 2015 Net income (loss) as reported $ (12,660 ) $ 8,008

Interest expense 27,617 1,120

Provision (benefit) for income taxes (102 ) 1,812

Depreciation 12,949 5,791

Amortization 9,464 3,387

EBITDA 37,268 20,118

IP related litigation 1,907 700

Stock-based compensation 2,029 2,253

Consolidation and optimization expenses 6,649 7,160

Acquisition and integration expenses 9,965 66

Asset dispositions, severance and other 4,526 629

Noncash (gain) loss on cost and equity method investments (639 ) (498 ) Adjusted EBITDA $ 61,705 $ 30,428

Adjusted EBITDA as a % of sales 18.6 % 18.9 %

* - During the third quarter of 2015, we changed our calculation and presentation of Adjusted EBITDA in order to present our financial results in a form more consistent with other medical device companies, as well as our debt covenant calculations. The primary difference between the current and former calculation is that stock-based compensation is now added back to GAAP net income (loss) to derive Adjusted EBITDA. Prior period adjusted amounts have been recalculated to be presented on a comparable basis.

28

Other Operating Expenses 2016

(in $ millions) Q1’15 Q2’15 Q3’15 Q4’15 2015 Q1’16

2014 Investments and Capacity and Capabilities $6.5 $6.3 $5.1 $5.2 $23.0 $4.2

Portable Medical and Vascular product line transfers

Orthopaedic Optimization $0.5 $0.5 $0.4 $1.4 $0.1

Legacy Lake Region Consolidation and Optimization

$2.0 $2.0 $2.4

Acquisition and Integration Costs $0.1 $0.1 $5.2 $28.1 $33.5 $10.0

Lake Region Medical and CCC Medical Devices

Asset Dispositions, Severance and Other $0.8 $0.9 $3.2 $1.7 $6.6 $4.5 Nuvectra spin off

Total OOE $7.9 $7.8 $13.8 $37.0 $66.5 $21.1

29

Contact Information

Tony Borowicz Vice President Business Development

& Investor Relations Greatbatch tborowicz@greatbatch.com Work: 716-759-5809 Mobile: 716-572-9972 www.greatbatch.com